中国医药
中國醫藥
중국의약
CHINA MEDICINE
2008年
12期
790-791
,共2页
肝癌%汉防已甲素%阿霉素%多药耐药
肝癌%漢防已甲素%阿黴素%多藥耐藥
간암%한방이갑소%아매소%다약내약
Hepatocellular carcinoma%Tetredrine%Adriamycin%Muhidrug-resistant
目的 研究汉防己甲素对人肝癌多药耐药细胞株Hep-3B/ADM耐药性的逆转作用及其机制.方法 通过阿霉素(ADM)浓度梯度递增诱导法,建立人肝癌多药耐药细胞株Hep-3B/ADM.MTT法检测细胞对化学疗法药物的敏感性;流式细胞仪检测细胞表面多药耐药基因表达产物P-170及分析细胞内若丹明123染剂相对荧光强度.结果 汉防己甲素(0.10~1.00 μmol/L)可逆转肝癌耐药细胞的耐药性;汉防已甲素明显降低细胞表面P-170的表达.结论 汉防己甲素具有增强阿霉素对Hep-3B/ADM细胞的毒性作用,其作用机制与逆转多药耐药基因有关.
目的 研究漢防己甲素對人肝癌多藥耐藥細胞株Hep-3B/ADM耐藥性的逆轉作用及其機製.方法 通過阿黴素(ADM)濃度梯度遞增誘導法,建立人肝癌多藥耐藥細胞株Hep-3B/ADM.MTT法檢測細胞對化學療法藥物的敏感性;流式細胞儀檢測細胞錶麵多藥耐藥基因錶達產物P-170及分析細胞內若丹明123染劑相對熒光彊度.結果 漢防己甲素(0.10~1.00 μmol/L)可逆轉肝癌耐藥細胞的耐藥性;漢防已甲素明顯降低細胞錶麵P-170的錶達.結論 漢防己甲素具有增彊阿黴素對Hep-3B/ADM細胞的毒性作用,其作用機製與逆轉多藥耐藥基因有關.
목적 연구한방기갑소대인간암다약내약세포주Hep-3B/ADM내약성적역전작용급기궤제.방법 통과아매소(ADM)농도제도체증유도법,건립인간암다약내약세포주Hep-3B/ADM.MTT법검측세포대화학요법약물적민감성;류식세포의검측세포표면다약내약기인표체산물P-170급분석세포내약단명123염제상대형광강도.결과 한방기갑소(0.10~1.00 μmol/L)가역전간암내약세포적내약성;한방이갑소명현강저세포표면P-170적표체.결론 한방기갑소구유증강아매소대Hep-3B/ADM세포적독성작용,기작용궤제여역전다약내약기인유관.
Objective To investigate reversal effect on Hep-3B/ADM by TTD and its mechanism.Methods An adriamycin-resistant human HCC cell line(Hep-3 B/ADM)was established.through exposure to gradually increased concentration of ADM.Drug sensitivity was measured by MTT.Flow cytometry(FCM)was performed to assess the expression of P-170 and the fluorescene intensity of Rh13 in the cells.Results TTD(0.10-1.00 μmoL/L)can reverse multidrug-resistant of Hep-3B/ADM.TTD decreased the expression of P-170 in the cells significantly.Conclusion TTD significantly enhancs ADM-induced cytotoxicity.The mechanism is mediated by inhibiting muhidrug-resistant(MDR1).